FAES FARMA, S.A.

Consensus Faes Farma, S.A.

Equities

FAE

ES0134950F36

Real-time Estimate Tradegate Other stock markets 09:39:30 2024-06-10 am EDT			5-day change	1st Jan Change
3.79 ^EUR	-0.26%		-0.13%	+19.78%

May. 23	FAES FARMA : Faes Farma is now receiving the long-awaited attention from investors
Apr. 26	FAES FARMA : Q1 beat; full-year guidance re-affirmed

Evolution of the average Target Price on Faes Farma, S.A.

Price target over the last 5 years

History of analyst recommendation changes

3cb68f3627a92ca4d7a6e93a6.mEsNyVj-5h-_mz04g1o71atRFaFnplWlwqb2WVBv4Tw.yT51hzqPiXfIrm911jRdpuo5bOYRlhbVtu-1NGcoinXxf2mQYYuVTsioTg~ec79a86dd41cceb55bc7b4b9684fac0e

Analyst Recommendations on Faes Farma, S.A.

FAES FARMA : Faes Farma is now receiving the long-awaited attention from investors	May. 23
FAES FARMA : Q1 beat; full-year guidance re-affirmed	Apr. 26
FAES FARMA : Q4 profitability exceeded expectations	Feb. 27
FAES FARMA : Mixed Q3; markets need more from Faes to be convinced	23-10-25
FAES FARMA : A soft Q2, as expected; guidance maintained	23-08-01
FAES FARMA : Increased R&D focus and inflationary pressures to hold back near-to-medium term earnings	23-07-12
FAES FARMA : A healthy start to 2023	23-05-08
FAES FARMA : 2022 guidance met + positive view maintained	23-03-06
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14
FAES FARMA : Soft Q3, but 2022 guidance maintained	22-10-28
FAES FARMA : Another stronger quarter but maintained full-year outlook	22-08-01
FAES FARMA : Strong Q1; but some moderation lies ahead	22-05-02
FAES FARMA : A strong Q4 sums up a decent 2021	22-03-02
FAES FARMA : An overall strong Q3	21-11-02
FAES FARMA : Base business recovers in Q2; FY21 outlook reiterated despite resurfacing COVID-19 concerns	21-07-28
TODAY'S ANALYST RECOMMENDATIONS : Cisco, easyJet, L Brands, Mattel, Salesforce...	21-05-21
FAES FARMA : Q1 21 – a mixed bag	21-05-04
FAES FARMA : Bilastine weighed on FY20; capacity expansion to cater underlying demand	21-03-03

More recommendations

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

4

Last Close Price

3.8 EUR

Average target price

3.7 EUR

Spread / Average Target

-2.63%

High Price Target

4.3 EUR

Spread / Highest target

+13.16%

Low Price Target

3.2 EUR

Spread / Lowest Target

-15.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Faes Farma, S.A.

alphavalue

Abhishek Raval

Ratings for Faes Farma, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

B

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Equities
FAE Stock
Consensus Faes Farma, S.A.

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer